表紙
市場調査レポート

旭化成ファーマの製品パイプライン分析

Asahi Kasei Pharma Corp. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 319961
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
旭化成ファーマの製品パイプライン分析 Asahi Kasei Pharma Corp. - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 42 Pages
概要

旭化成ファーマはファーマシューティカル企業であり、ヒト型酵素、デヒドロゲナーゼなどの酵素製品や、食品添加物、診断用試薬、栄養剤、アニマルヘルス製品、コンタクトレンズなどを提供しています。

当レポートでは、旭化成ファーマにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

旭化成ファーマの基本情報

  • 旭化成ファーマの概要
  • 主要情報
  • 企業情報

旭化成ファーマ:R&Dの概要

  • 主な治療範囲

旭化成ファーマ:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

旭化成ファーマ:パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 登録申請前段階の製品/併用療法モダリティ
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

旭化成ファーマ:薬剤プロファイル

  • collagenase clostridium histolyticum
  • thrombomodulin alfa
  • zoledronic acid
  • AK-106
  • elcatonin
  • fasudil
  • pentosan polysulfate sodium
  • ATS-8535
  • Small Molecules to Antagonize EP1 Receptor for Overactive Bladder
  • Small Molecule for Rheumatoid Arthritis and Autoimmune Diseases
  • Small Molecules to Inhibit ADAMTS-5 for Undisclosed Indication

旭化成ファーマ:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

旭化成ファーマ:最新のパイプライン情報

旭化成ファーマ:開発休止中のプロジェクト

旭化成ファーマ:開発が中止された製品

旭化成ファーマ:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07896CDB

Summary

Global Markets Direct's, 'Asahi Kasei Pharma Corp. - Product Pipeline Review - 2015', provides an overview of the Asahi Kasei Pharma Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Asahi Kasei Pharma Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Asahi Kasei Pharma Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Asahi Kasei Pharma Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Asahi Kasei Pharma Corp.'s pipeline products

Reasons to buy

  • Evaluate Asahi Kasei Pharma Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Asahi Kasei Pharma Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Asahi Kasei Pharma Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Asahi Kasei Pharma Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Asahi Kasei Pharma Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Asahi Kasei Pharma Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Asahi Kasei Pharma Corp. Snapshot
    • Asahi Kasei Pharma Corp. Overview
    • Key Information
    • Key Facts
  • Asahi Kasei Pharma Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Asahi Kasei Pharma Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Asahi Kasei Pharma Corp. - Pipeline Products Glance
    • Asahi Kasei Pharma Corp. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Asahi Kasei Pharma Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Asahi Kasei Pharma Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Drug Profiles
    • Asahi Kasei Pharma Corp.
  • zoledronic acid
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • mizoribine
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • thrombomodulin alfa
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • AK-106
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • elcatonin
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • fasudil
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • pentosan polysulfate sodium
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • ATS-8535
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Small Molecules to Antagonize EP1 Receptor for Overactive Bladder
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Small Molecule for Rheumatoid Arthritis and Autoimmune Diseases
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Asahi Kasei Pharma Corp. - Pipeline Analysis
    • Asahi Kasei Pharma Corp. - Pipeline Products by Target
    • Asahi Kasei Pharma Corp. - Pipeline Products by Route of Administration
    • Asahi Kasei Pharma Corp. - Pipeline Products by Molecule Type
    • Asahi Kasei Pharma Corp. - Pipeline Products by Mechanism of Action
  • Asahi Kasei Pharma Corp. - Recent Pipeline Updates
  • Asahi Kasei Pharma Corp. - Dormant Projects
  • Asahi Kasei Pharma Corp. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • teriparatide acetate transdermal patch
  • Asahi Kasei Pharma Corp. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Asahi Kasei Pharma Corp., Key Information
  • Asahi Kasei Pharma Corp., Key Facts
  • Asahi Kasei Pharma Corp. - Pipeline by Indication, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Stage of Development, 2015
  • Asahi Kasei Pharma Corp. - Monotherapy Products in Pipeline, 2015
  • Asahi Kasei Pharma Corp. - Partnered Products in Pipeline, 2015
  • Asahi Kasei Pharma Corp. - Partnered Products/ Combination Treatment Modalities, 2015
  • Asahi Kasei Pharma Corp. - Pre-Registration, 2015
  • Asahi Kasei Pharma Corp. - Phase III, 2015
  • Asahi Kasei Pharma Corp. - Phase II, 2015
  • Asahi Kasei Pharma Corp. - Preclinical, 2015
  • Asahi Kasei Pharma Corp. - Discovery, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Target, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Route of Administration, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Molecule Type, 2015
  • Asahi Kasei Pharma Corp. - Pipeline Products by Mechanism of Action, 2015
  • Asahi Kasei Pharma Corp. - Recent Pipeline Updates, 2015
  • Asahi Kasei Pharma Corp. - Dormant Developmental Projects,2015
  • Asahi Kasei Pharma Corp. - Discontinued Pipeline Products, 2015

List of Figures

  • Asahi Kasei Pharma Corp. - Pipeline by Top 10 Indication, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Stage of Development, 2015
  • Asahi Kasei Pharma Corp. - Monotherapy Products in Pipeline, 2015
  • Asahi Kasei Pharma Corp. - Partnered Products in Pipeline, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Top 10 Target, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Asahi Kasei Pharma Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top